1642

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

he Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL **FORM**

(to be used for all correspondence after initial filing)

Date

10/048.046 Application Number 01/24/2002 Filing Date Thanos Halazonetis et al First Named Inventor Group Art Unit **Examiner Name**

WST97AUSA 5 Attorney Docket Number Total Number of Pages in This Submission **ENCLOSURES** (check all that apply) Assignment Papers After Allowance Communication Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeals and Interferences

Appeal Communication to Group CH (Appeal Notice, Brief, Reply Brief)

Proprietary Information

Status Letter

Other Enclosure(s) (please identify below):

Copies of (6) documents Licensing-related Papers Amendment / Reply After Final Petition to Convert to a Affidavits/declaration(s) Provisional Application Power of Attorney, Revocation Change of Correspondence Extension of Time Request Address Terminal Disclaimer Express Abandonment Request Request for Refund Information Disclosure Statement CD, Number of CD(s) _ are attached herewith Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application BEST AVAILABLE COPY Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Mary E. Bak, Esquire Individual name Howson and Howson Signature

	CERTIFICATE OF MA	ILING	
	ondence is being deposited with the United States to: Commissioner for Patents, Washington, DC 20	s Postal Service w	nth sufficient postage as first class 10/03/2002
Typed or printed name	Debra N. Gerstemeier		
Signature	1019 temen	Date	10. S-2ms

Burder Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



00270 PATENT TRADEMARK OFFICE

TECH CENTER 1600/290

WST97AUSA

W319/AU3A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit:

Examiner:

) Apple No. 10/048 046

Appln. No. 10/048,046

Filed: January 24, 2002

For: COMPOSITIONS AND METHODS TO) October 3, 2002

ENHANCE SENSITIVITY OF CANCER CELLS TO MITOTIC STRESS

Commissioner for Patents

BEST AVAILABLE COP

U.S. Patent and Trademark Office Washington, DC 20231

In re the Application of

Thanos Halazonetis et al

SECOND INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR §1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the references are enclosed herewith.

According to 37 CFR §1.97(c) and §1.97(e), Applicants and the undersigned attorney hereby certify that each item of information contained herein was previously cited in the Supplementary Partial European Search Report mailed on September 2, 2002 in corresponding European Patent Application No. 00944679.0, filed on June 14, 2000. Document (BT) was previously cited and provided to the Examiner in an Information Disclosure Statement filed on June 3, 2000. Therefore, a copy of this document is not provided herewith. A copy of the Report is enclosed together with copies of the documents not previously submitted.

CERTIFICATE UNDER 37 CTR §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: the Commissioner for Patents, Washington, DC 20231 on October 3, 2002.

signature

Typed or printed name

Debra N. Gerstemeier

This Information Disclosure Statement is submitted within three months of issuance of the above-cited Supplementary Partial European Search Report, and prior to receipt of a first Office Action on the merits. Therefore, no fees are believed due. However, the Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

The Examiner is respectfully requested to consider the documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of the examination of this application.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for the Applicants

By Mary E. Bak

Registration No. 31,215

Spring House Corporate Center

Box 457

Spring House, PA 19477

Telephone: (215) 540-9206 Telefacsimile: (215) 540-5818

BEST AVAILABLE COPY

 (\cdot) inside this box $\rightarrow \blacksquare$

				U.S. PATENT DOCUMEN	TS	
Examiner	Cite	U.S. Pate	U.S. Patent Document	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, Lines, Where Relevant
Initials* No 1	Number	Kind Code ² (if known)	Cited Document	Cited document MM-DD-YYYY	Passages or Relevant Figures Appear	
					BES'	T AVAILABLE COPY

				FOR	EIGN PATENT DOCUMENTS			
Examiner Initials	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	Le	
		Office ³		Code ⁵ nown)		MM-DD-YYYY	Passages or Relevant Figures Appear	
٠	AL	WO	WO99/11 7 95	Al	ICOS Corporation	03/11/1999		
•	AM	EP	1,074,617	A2	Helix Research Institute	02/07/2001		

Examiner		Date	
Signature		Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPFP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

⁴Unique citation designation number ⁻²See attached Kinds of U.S. Patent Documents ⁻³Enter Office that issued the document, by the two-letter code (WIPO Standard S1/3) ⁻⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1 16 if possible. "Applicant is to place a check mark here if English language Translation is attached."

+9A/PTO	Complete if Known				
.11ON DISCLOSURE .4ENT BY APPLICANT	Application Number	10/048,046	E		
(use as many sheets as necessary)	Filing Date	January 24, 2002	HC	00	
OIPE	First Named Inventor	Thanos Halazonetis et al	CENTE		
007 1 9 22	Group Art Unit		ਤ	5 20	
2 VCT 0 9 2002 **	Examiner Name		00/29	2002	
She company 2 of 2	Attorney Docket Number	WST97AUSA	8		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiners Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AAZ ,	G. ZHU et al, "The Fork Head Transcription Factor Hcm1p Participates in the Regulation of SPC110, Which Encodes the Calmodulin-Binding Protein in the Yeast Spindle Pole Body", Biochimica et Biophysica Acta, 1448(2):236-244 (December, 1998)	
	BR 、	B. OUYANG et al, "Human Bub1: a Putative Spindle Checkpoint Kinase Closely Linked to Cell Proliferation", Cell Growth & Differentiation, 9(10):877-885 (October, 1998)	
	BS 、	K. HARDWICK, "The Spindle Checkpoint", Trends in Genetics, 14(1) 1-4 (January, 1998)	
	BT	D. CAHILL et al, "Mutations of Mitotic Checkpoint Genes in Human Cancers", Nature, 392:300-303 (March, 1998)	
	BU \	D. SCOLNICK et al, "Chfr Defines a Mitotic Stress Checkpoint that Delays Entry into Metaphase", Nature, 406(6794) 430-435 (July, 2000)	
		BEST AVAILABLE COPY	

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.